dr schucheng zhang, vice president, sinovet (beijing) biotechnology co ltd
TRANSCRIPT
October 19-20, 2016
Innovation Quality Service
Sinovet (Beijing) Biotechnology Co., Ltd
Shucheng Zhang, DVM, PhD
Sinovet
• A private research-based company • Business focus: Animal biological
product development, manufacture, and marketing
• Company core value: innovation, quality, and service
Sinovet (Beijing) Biotechnology Co.,
Ltd ,
Sinovet (Jiangsu) Biopharmaceutical Co., Ltd
China Medical City , Taizhou
Sinovet Sites
Fact of SinovetSinovet (Beijing) was established in 2010 after splitting from another
biological company (Headquarter + Marketing)Sinovet (Jiangsu) was established in 2011 in China Medical City in
Taizhou, Jiangsu ( Production + R&D + Marketing)Major business units: R&D, Production, and MarketingEmployee: 200 plus Investment Capital : US$ 30 millionsRevenue (2015) : US$ 10 millions
Board of Directors
Wu, Hua Chairman, President
Zhao, Jianzeng Director
Vice-President Marketing
Wu, Qiong Director
Vice-President HR and Finance
Wang, Wei Secretary,GM, R&D RegulatoryBusiness
Zhang, Shucheng Director
Vice-President Manufacture
and R&D
Company Structure
Board of Directors
President
Marketing R&D Center Production
Legal/ Business Finance HR
Wu, Hua President , CEO
Zhao, Jianzeng
VP, Marketing Lu, Wei
General Manager, South China
Regions
Tian, Changxiao General Manager
Key Customer Account
Chen, Lei,General Manager,
North China Regions
Shi, XinchuanGeneral Manager Bovine Products
Zhang, Shucheng VP, R&D,
Production
Su, Weiwei, General Manager, Sinovet (Jiangsu),
Production, QC, QA
Wang, WeiGeneral Manager , R&D RA, Business,
Networking
Xia MingqiAssociate General M , R&D Swine
Diseases
He, Yanliang Associate General M,
R&D Small Animal Diseases
Li, Zhenguang Associate General M, R&D Bovine Diseases
Wu, Qiong VP, HR,
Finance
Wu , Yingying Associate General Manager, Finance
Xu, Jianjun Manager, Human
Resource
Sinovet Leadership Team
Milestones of Sinovet
2013
2010
2011
2012 2014 2016
2015
Sinovet (Beijing) established
Sinovet (Jiangsu) establishedHP PRRS vaccine licensed
HP-PRRS/CSF combo vaccine clinical trial
Two production lines accredited for GMP
HP PRRS-CSF combo vaccine licensed
Two more production lines accredited for GMP PRV, HP-PRRS (bioreactor), BVD licensed First product (CSF) on market
Sinovet (Jiangsu) construction completed
R&D Center Research Teams: 35+ scientists Research Focus: Animal (swine, bovine, C&A )
vaccines and diagnostic reagents/kits Key Technologies/resources
Suspension cell technology Lyophilization/Stabilizer platform Genetic engineering technology Network and collaborations Local strain access and acquisition through surveillance
program
R&D Center
R&D Center Swine
HP–PRRSLive
PRRS-CSF Combo
PRRS-CSF-PRV Combo
PRRS-PRV combo
SIV
PCV2
Bovine
BVD, Killed
BVD-IBRKilled
BVD-IBR Live
Bovine Multiple Combo
Small Animal
MEV-CDV live
Bacterial Vaccines
Rabies
Technology
Suspension cells
Adjuvant
Vaccine Processing
Business/ Regulatory
Regulatory Affairs
IP
Networking
Business and Legal
Diagnosis
Monoclonal antibodies
Diagnostic kits
Tech service support
R&D Laboratories
R&D Teams
Sinovet Pipelines
Post 2020Pre 2014 2015 2016 2017 2018 2019
HP-PRRS
/CSF
Combo
HP-PRRS (
Bioreac
tor)
CSF (
Cell)
BVD ki
lled
PRV (B
arth
a K61
)
HP-PRRS/
PRV Li
ve Co
mbo
BVD /I
BR Killed Co
mboBV
D/IBR Li
ve Co
mbo
MEV
/CPV
(Mink
) Live
Combo
CSF (
co/IF
A as Q
C tes
t )
HP PRRS (
RB)
HP-PRRS/
CSF/
PRV Li
ve Co
mbo
PCV2 M. hyo PCV2/M. hyo combo PED/TGE combo Cattle 5-way vaccine Diagnostic kits
SIV Biva
lent k
illed
SSinovet New Product Projection
2010 2011 2012 2013 2014 2015 2016 2017 2018 2019 2020 20110
2
4
6
8
10
12
14
16
18
20
Existing products New Products
Num
ber o
f Pro
duct
s
Innovation Example I HP-PRRS/CSF Live Combo Vaccine
Innovation Points:• First PRRS/CSF combo vaccine • Most safe vaccine HP PRRSV strain with
double gene deletions • PRRS vaccine strain without
immunosuppression and interference to other vaccines
• Innovation testing method for CSF final product
Innovation Example II Suspension Cell Technology
MDCK Cells
Marc-145 Cells
Adherence Cells Suspension Cells
Highlights:
- Serum free medium- No micro- carrier- High virus titer - Proprietary technology
Intellectual Properties
• Chinese patents• Published - 12 • Pending application - 4
• International patents • Published - 3 (filed in 15
countries )• Pending application - 1
• Trademarks• Approved - 1• Pending applications - 25
Manufacture
M
Manufacture Team
Production Capacity and Production Lines
Capacity of production facility ( 400 M)• Live viral vaccine - 200 million dose • Killed viral vaccine – 120 million dose • Killed bacterial vaccine – 80 million dose
GMP-certified production lines Live virus vaccine (Roller Bottles) Live virus vaccine (Bioreactors) Killed virus vaccine (Roller Bottles) Killed bacterial vaccine (Fermenter)
Production lines to be established (phase II) Killed virus vaccine (Bioreactors) Live bacterial vaccine
Manufacture Space and Environment 冻干系统
Bioreactors (500L)
Vaccine Mixing and Assembly Lines
Product Quality Control
• Experienced management Team
• Well-trained team for each position
• State-of-art Facility
• Strictly enforced GMP system
Manufacture/ Management
Quality Control
Quality Assurance
• Raw material• Package
materials • Antigen batches
and critical reagents
• Final product • Regular
environment monitoring
• Water system
• Manufacture process and environment
• Water and gas supply system
• Product release process
• Costumer feedback
• Documentation system
Marketing and Technical Service
Marketing and Technical ServiceOrganization
Marketing
Sales
South China
North China
Large Farms
Technical Service
Tech Service Team
Diagnostic Lab
Training and Technical Service
Major Partners and Collaborators
Institute of Veterinary Drug Control Pfizer (Zoetis) Animal Health Tiankang Animal Health China Animal Husbandry Group
Government Sponsored Researches
Name of Project Sponsors Funding Studies on diagnostic technology of cattle and sheep
MOST US$ 200K
Studies on prevention/control technology of major infectious diseases of cattle and sheep
MOST US$ 1000K
Stress effect on bovine respiratory diseases MOST US$ 200KStudies on lyophilization/stabilizer for cattle vaccines
MOST US$ 500K
Studies on animal vaccine technology MOST US$ 200KStudies on cell suspension for animal vaccine development
MOA US$ 170K
Industrialization research on CSF/PRRS combo vaccine
JPST US$ 900K
PRSSV differential diagnosis JPST US$ 40K
MOST: Ministry of Science and Technology; MOA: Ministry of Agriculture; JPST: Jiangsu Province Science and Technology Department
Research Collaborations with Universities and Research Institutes
Research Collaborations with University and Research Institutes
Collaborations with Pfizer/Zoetis
Collaborations with Animal Health Companies
Sinovet - A Leader for Future
THANK YOU
Website: www.sinovetah.com